SARS-CoV-2, the virus that causes COVID-19, has developed a unique mutation that may play a role in disease transmission. Blocking its main receptor, ACE2, does not completely eliminate infection, suggesting the possibility of another receptor. Integrins are upregulated during COVID-19 and may be targeted by this evolutionary mutation. We have studied the mechanisms behind SARS-CoV-2 and integrin binding, and found this interaction may cause cardiovascular damage in severe COVID-19. In addition, we have investigated the integrin-blocker drug, Cilengitide, and its ability to prevent the virus from attaching to human cells, revealing the potential of a new antiviral treatment.